

---

**Product Data Sheet**

---

Product Name: YM348  
Cat. No.: GC31503

**Chemical Properties**

Cas. No. 372163-84-3

SMILES C[C@H](N)CN(N=C1)C2=C1C=CC3=C2C=C(CC)O3

Formula  $C_{14}H_{17}N_3O$  M.Wt 243.3

Solubility DMSO : 100 mg/mL (411.02 mM; Need ultrasonic) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

**Protocol**

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

Experiments are performed with membranes obtained from Chinese Hamster Ovary (CHO) cells expressing human 5-HT<sub>2C</sub> or 5-HT<sub>2A</sub> receptors and Human Embryonic Kidney 293-Epstein-Barr virus nuclear antigen (HEK293-EBNA) cells expressing human 5-HT<sub>2B</sub> receptors. Binding assays with [<sup>3</sup>H] 5-HT are carried out. The reaction medium (50 mM Tris-HCl buffer (pH 7.4) containing 4 mM CaCl<sub>2</sub>, 10 M pargyline and 0.1 mg/ml L-(+)-ascorbic acid) containing [<sup>3</sup>H] 5-HT, membrane preparation and test compounds are incubated at 37°C for 30 min. Nonspecific binding is determined in the presence of 10 M 5-HT, and specific binding is calculated as the total binding minus the nonspecific binding. After incubation, 4 mL of 50 mM Tris-HCl buffer (pH 7.4) containing 4 mM CaCl<sub>2</sub> is added, and the medium is filtrated under decompression through a Whatman GF/B glass filter pretreated with 0.1% polyethyleneimine. The filter is washed with the same buffer solution (4 mL×3). The glass filter is immersed in 6 mL of liquid scintillator (Packard, Aquasol-2), and the radioactivity is measured with a liquid scintillation counter. The amount of protein is measured. The dissociation constants (K<sub>d</sub> values) are obtained by Scatchard analysis using SAS (ver. 6.11). The concentrations of compounds showing 50% inhibition of receptor binding, IC<sub>50</sub> values, are obtained by nonlinear analysis using SAS (ver. 6.11). The K<sub>i</sub> values indicating affinity for receptors are calculated[1].

### **Kinase experiment:**

### **Animal experiment:**

Rats[1] Male Wistar rats (215-350 g) are used. Rats are administered YM348 (0.0677, 0.203, 0.677, and 2.03 mg/kg) orally and moved again to their home cages. After 20 min, thereafter, the rats are individually placed in transparent acrylic plastic cages (35×30×18 cm), and their motor activity is measured for 40 min. The measurements are carried out using a SUPER-MEX sensor. SB242084 (0.1-3 mg/kg i.p.) is administered 30 min before YM348 treatment.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

### References:

[1]. Kimura Y, et al. Pharmacological profile of YM348, a novel, potent and orally active 5-HT<sub>2C</sub> receptor agonist. Eur J Pharmacol. 2004 Jan 1;483(1):37-43.

### Background

YM348 is a potent and orally active 5-HT<sub>2C</sub> receptor agonist, which shows a high affinity for cloned human 5-HT<sub>2C</sub> receptor (K<sub>i</sub>: 0.89 nM).

YM348 has high affinity for cloned human 5-HT<sub>2C</sub> receptors with a K<sub>i</sub> value of 0.89 nM and lower affinities for human-cloned 5-HT<sub>2B</sub> (K<sub>i</sub>: 2.5 nM) and 5-HT<sub>2A</sub> receptors (K<sub>i</sub>: 13 nM). To assess the binding specificity of YM348, a broad evaluation of an additional 46 binding sites including several other 5-HT receptor subtypes (1A, 1B, 1D, 3, 4, 5A, 6, 7) is performed. IC<sub>50</sub> values of YM348 are found to be >1 μM for all of the binding sites except for the human 5-HT<sub>1A</sub> receptors (K<sub>i</sub>: 130 nM), bovine 5-HT<sub>1D</sub> receptors (K<sub>i</sub>: 481 nM), human 5-HT<sub>7</sub> receptors (K<sub>i</sub>: 177 nM), and human α<sub>2A</sub> receptors (K<sub>i</sub>: 126 nM). YM348 exhibits a full-agonistic activity on human 5-HT<sub>2A</sub> and 5-HT<sub>2B</sub> receptors. The EC<sub>50</sub> values of YM348 for 5-HT<sub>2C</sub>, 5-HT<sub>2A</sub>, and 5-HT<sub>2B</sub> receptors are 1.0, 93 and 3.2 nM, respectively[1].

Oral administration of YM348 induces penile erections and hypolocomotion in rats, being completely inhibited by a selective 5-HT<sub>2C</sub> receptor antagonist, SB242084. YM348 inhibits spontaneous activity in a dose-dependent manner with a minimum effective dose of 0.203 mg/kg[1].

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

## Product Data Sheet

---

[1]. Kimura Y, et al. Pharmacological profile of YM348, a novel, potent and orally active 5-HT<sub>2C</sub> receptor agonist. Eur J Pharmacol. 2004 Jan 1;483(1):37-43.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**